FIGURE 2.

Mxi1 is upregulated in PASMCs of HPH patients. Lung samples of three donors, three chronic lung disease (CLD) patients and three hypoxic pulmonary hypertension (HPH) patients were collected and sectioned. (A) Hemodynamic analysis of patients before collection of samples. (B) Hematoxylin and eosin staining of paraffin-fixed lung sections was used for morphological analysis of pulmonary arteries. (C) The expression of Mxi1 was examined via Western blotting analysis, followed by quantification of the blots through densitometry and normalization to β-actin. (D) Representative paraffin lung tissue sections from donors, CLD, and HPH patients were subjected to immunohistochemical staining of Mxi1. (E) Representative sections in all groups were also subjected to immunofluorescence staining of Mxi1 and α-SMA with nuclei counterstained by DAPI (blue), and the image of HPH merge was zoomed. Scale bar, 20 μm. Data are shown as means ± SDs. For statistical significance, ^***represents p < 0.001 compared with HPH patients.